Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled studyAngelo Sangiovanni, Giorgio Minoli, Rino Morales et al.|Hepatology|1998Cited by 91
X Chromosome Contribution to the Genetic Architecture of Primary Biliary CholangitisRosanna Asselta, Pietro Andreoné, Elvezia Maria Paraboschi et al.|Gastroenterology|2021Cited by 53
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosisPietro Lampertico, M. Colombo, E. Minola et al.|Digestive and Liver Disease|2014Cited by 23
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II studyRoberta D’Ambrosio, S. Fagiuoli, L. Pasulo et al.|Journal of Hepatology|2018Cited by 12
OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICEPietro Lampertico, M. Colombo, R. Soffredini et al.|Digestive and Liver Disease|2012Cited by 11